In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use

[cafead]

via After a delay to review additional data, the FDA has approved GSK’s momelotinib, now branded Ojjaara, to treat intermediate- or high-risk myelofibrosis in patients with anemia. In a pleasant surprise for Ojjaara, the FDA approved the medicine for patients with the blood cancer regardless of their treatment history.

article source